Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Antibody Fragments Market Growth From $12.31 Billion In 2026 To $17.56 Billion By 2030 At A CAGR Of 9.3%
The antibody fragments market size has experienced significant expansion in recent years. It is anticipated to grow from $11.26 billion in 2025 to $12.31 billion in 2026, reflecting a compound annual growth rate (CAGR) of 9.3%. This historical growth can be attributed to the advancement of monoclonal antibody technologies, the clinical success of antibody-derived therapies, the increasing research into cancer biologics, the broader expansion of diagnostic antibody usage, and enhanced investment in biologics research and development.
The antibody fragments market is set for substantial growth over the next few years, with projections indicating it will reach $17.56 billion by 2030, growing at a compound annual growth rate (CAGR) of 9.3%. This expansion during the forecast period can be attributed to the rise in targeted cancer therapies, the widening scope of antibody fragment pipelines, an increasing demand for precision biologics, the expanding application in companion diagnostics, and innovations within recombinant antibody engineering. Prominent trends for this period include the rising adoption of fragment-based biologics, their increasing utilization in oncology and specific therapeutic interventions, a growing demand for high-penetration antibody formats, the broadening of diagnostic applications, and an enhanced focus on treatments designed for reduced immunogenicity.
Get A Free Sample Report With In-Depth Market Insights:
Antibody Fragments Market Industry Drivers: What’s Behind The Revenue Growth?
The anticipated expansion of the antibody fragments market is driven by the rising occurrence of target diseases. These are specific illnesses or health conditions that medical interventions or research aim to prevent, manage, or cure. Key target diseases encompass cancer, infectious diseases, and bacterial infections. The elevated incidence of these target diseases primarily stems from unhealthy lifestyle choices and pollution, which weaken the body’s defenses, leading to chronic illnesses. Antibody fragments present highly specific, targeted, and adaptable therapeutic options for various diseases, often with reduced side effects compared to traditional therapies. Their capacity for customization and engineering to target specific ailments renders them an increasingly valuable tool in modern medicine. For instance, a January 2025 report from the American Cancer Society, a US-based non-profit organization, projects 2,041,910 new cancer cases and 618,120 cancer deaths in the United States in 2025. This represents an increase from 2,001,140 new cases and 611,720 deaths reported in 2024. Hence, the growing prevalence of target diseases is a key factor propelling the growth of the antibody fragments market.
Antibody Fragments Market Segment Breakdown: Which Categories Lead On Revenue?
The antibody fragments market covered in this report is segmented –
1) By Type: F(ab) Fragments, F(ab’)2 Fragments, Single-Chain Variable Fragments (scFvs), Single Domain Antibody Fragments (sdAbs), Other Types
2) By Specificity: Monoclonal Antibody, Polyclonal Antibody
3) By Delivery Method: Intravenous (IV), Subcutaneous (SC)
4) By Application: Cancer, Immunodeficiencies, Other Applications
5) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutions, Diagnostic Laboratories, Contract Research Organizations (CROs)
Subsegments:
1) By F(ab) Fragments: Recombinant F(ab) Fragments, Enzymatically Derived F(ab) Fragments
2) By F(ab’)2 Fragments: Pepsin-Derived F(ab’)2 Fragments, Recombinant F(ab’)2 Fragments
3) By Single-Chain Variable Fragments (scFvs): Bacterial-Produced Single-Chain Variable Fragments (scFvs), Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs), Yeast-Produced Single-Chain Variable Fragments (scFvs)
4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs), Shark-Derived Single Domain Antibody Fragments (sdAbs), Synthetic Single Domain Antibody Fragments (sdAbs)
5) By Other Types: Bispecific Antibody Fragments, Multispecific Antibody Fragments, Fusion Protein Antibody Fragments
#Antibody Fragments Market Growth Trends: What’s Shaping The Future Outlook?
Leading companies within the antibody fragments market are concentrating on advancing clinical trials to create novel products, including human VH antibody fragments. This endeavor aims to bolster the efficacy of targeted therapies and mitigate immunogenicity in addressing conditions like cancers, autoimmune disorders, and infectious diseases. A human VH antibody fragment represents the variable domain of a human antibody’s heavy chain, which possesses the ability to independently bind to antigens. It contributes to the formation of antibody fragments by acting as the crucial antigen-binding region, frequently employed either in isolation or combined with other molecules to produce compact, stable, and high-affinity therapeutic or diagnostic antibodies. As an illustration, Zai Lab Limited, a pharmaceutical company based in China, commenced a global Phase 2 clinical trial in May 2024 to assess the effectiveness and safety of ZL-1102. This ZL-1102 is a groundbreaking human VH antibody fragment (Humabody) designed to target IL-17. Its development focuses on a topical therapy for mild-to-moderate chronic plaque psoriasis, with the objective of enhancing treatment precision and diminishing systemic side effects and immunogenic reactions.
Antibody Fragments Market Leading Players And Competitive Positioning
Major companies operating in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.
View The Full Antibody Fragments Market Report:
Antibody Fragments Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the antibody fragments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody fragments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model